Brenda Pope joined BioCrossroads in January 2005 as Executive Assistant for David Johnson, President and CEO. Previously she worked at the law firm of Baker & Daniels for 15 years.
As Project Director for BioCrossroads, a non-profit organization advancing Indiana’s life sciences industry, Stemme is responsible for identifying and developing opportunities for collaboration between Indiana’s life sciences companies and research universities. In this role, Stemme manages BioCrossroadsLINX, an initiative focused on leveraging Indiana’s strengths in pharmaceutical development and manufacturing. He also serves as a key contributor to BioCrossroads’ market research division, BioIntellex, drafting reports on Indiana’s contract drug development, medical device and health information technology sectors. He supports the State’s economic development agency by providing market information to attract and grow life sciences companies in Indiana and serves as an advisor to Indiana Seed Fund II, assisting the fund manager in deal sourcing, diligence and execution of portfolio investments. He currently serves on the boards of Aarden Pharmaceuticals, AgeneBio and Muroplex Therapeutics.
Prior to joining BioCrossroads in 2005, Stemme was employed by Eli Lilly and Company as a Senior Associate in the company’s Corporate Affairs group, where he ran the company’s political action committee. He also worked as a Financial Analyst in the company’s biotechnology unit and was a member of the team that established Lilly Systems Biology, Ltd. in Singapore. Previously, Stemme was a Manager in Arthur Andersen’s Assurance practice, providing audit and tax consulting to companies in the energy, software and healthcare industries.
Stemme currently serves in a number of volunteer community roles, including the Bloomington Life Sciences Partnership Advisory Board and Special Projects Council for The Children’s Museum of Indianapolis. In 2002, Stemme was one of 25 Indianapolis leaders selected to participate in the Stanley K. Lacy Executive Leadership Series. He holds a degree in Accounting from Butler University in Indianapolis, where he has served as President of the University’s Alumni Association and was a member of the Board of Trustees.
Chris Eckerle serves as Project Director for BioCrossroads. In this capacity, Eckerle focuses on promoting the entrepreneurial and institutional opportunities throughout Indiana’s life science community. He manages the BioCrossroads New Venture Competition and supports the Indiana Biosciences Research Institute and OrthoWorx, a Warsaw-based initiative to advance the region’s significant orthopedics device sector. Eckerle also serves as an advisor to the Indiana Seed Fund II and assists the fund manager in deal sourcing, diligence and execution of portfolio investments.
Prior to joining BioCrossroads, Eckerle spent several years as the Director of Life Sciences for the Indiana Economic Development Corporation, where he led the state’s initiative to expand, attract, and retain life sciences corporations. He served on the board of directors for Indiana Health Information Technology, Inc. and the Indiana Cord Blood Bank. Previously, he also oversaw Indiana’s Health and Human Service agencies while at the Office of Management and Budget.
Eckerle earned a BS in Biology from Yale University, where he was a two-time Academic All-American, and an MBA from the Krannert School of Management at Purdue University.
Daniel H. Robertson, Ph.D.
Visiting Research Fellow
Daniel H. Robertson, a proven and experienced technical leader in information technology (IT), computational science and research, is a visiting research fellow at the IBRI focused on defining and developing the institute’s computational analytics and data science capabilities.
Prior to joining the IBRI, Dr. Robertson served as senior director of research IT at Eli Lilly and Company where he led the IT team supporting discovery systems and processes across six global research sites and nine functional/therapeutic areas. In his leadership role, Dr. Robertson was instrumental in delivering emerging technology and analyses through informatics resources, enhancing support for big data storage and analysis, and transforming IT support for Open Innovation Drug Discovery program to a high-performing DevOps team, which was recognized with an InformationWeek 500 award.
Dr. Robertson has worked for Eli Lilly and Company for more than 15 years, first as a research scientist at Lilly Research Laboratories, then as a group leader and director of scientific informatics and global computational drug discovery.
He earned his Ph.D. in Physical Chemistry from Florida State University and his bachelor’s of science degree in chemistry, graduating Summa Cum Laude, from Florida Southern College. After earning his Ph.D., Dr. Robertson served as an NRC/NRL Postdoctoral Research Associate at the Naval Research Laboratory in Washington, D.C., and then held several positions at Indiana University-Purdue University Indianapolis (IUPUI) from 1993 through 2000. He last served as associate scientist and director of technical and administrative services and manager of the Facility for Computational Molecular Science at IUPUI before joining Eli Lilly and Company in 2000.
Dr. Robertson has published 67 papers in refereed journals, authored three invited book chapters, and conducted more than 65 professional/technical presentations. He has been honored with multiple awards from Eli Lilly and Company and IUPUI, and is a member of the American Chemical Society, American Physical Society and physics and mathematics honoraries.
David L. Johnson
David L. Johnson was elected President and CEO of the Central Indiana Corporate Partnership (CICP), a regional strategic collaboration of business leaders and university presidents, in December 2012. He also continues to serve as President of CICP’s BioCrossroads life sciences initiative.
Johnson has been engaged with CICP for more than a decade as one of the original organizers and chief executive of BioCrossroads, a market-based enterprise focused on collaboration and strategic investments for growing Indiana’s life sciences sector. Among its many activities, BioCrossroads informs and educates; raises and invests venture capital funds in promising new companies; and builds business collaborations by bridging gaps across academia and industry.
Through his work at BioCrossroads, Johnson has been responsible for raising over $300 million dollars in philanthropic, corporate and venture capital funding to advance new companies, promote innovative research, and deliver on the promise of highly skilled 21st-Century employment opportunities for Hoosiers.
He had previously been a partner in the Indianapolis-based law firm of Baker & Daniels for nearly 20 years where he advised corporate and public sector clients on issues of economic development, public and project financing and capital formation.
Mr. Johnson is an honors graduate of Harvard University, Harvard Law School and Oxford University, where he studied as a Rhodes Scholar.
Julie Routt is BioCrossroads’ office manager. Julie has been with BioCrossroads since 2003. Prior to joining the organization, Julie worked at the Indy Partnership, the Indianapolis Mayor’s Office, and the Indianapolis Zoo. She is a graduate of Tri-State University in Angola, Indiana.
Lori LeRoy serves as Public Relations and Marketing Director for BioCrossroads and leads their public/media relations activities as well as their internal and external communications strategies. She also directs advertising and general marketing activities.
LeRoy was previously marketing manager, communications for Roche Diagnostics Diabetes Care business area. She was also a public relations consultant at Roche where she managed product public relations for its laboratory, hospital, physician’s office and research products. With a strong background in consumer PR, brand awareness campaigns and health care/technology PR, she has also held positions as senior manager, corporate communications at Philips Consumer Electronics and corporate communications manager at AirTran Airways.
She earned a B.A. in English and Asian Studies from Oglethorpe University in Atlanta, where she also served as a member of the Alumni Association Board of Directors.
Nora Doherty joined BioCrossroads in 2003 after working many years with entrepreneurial companies. She is vice president of finance for BioCrossroads and managing director for its Seed Funds. In this role, she serves on the Board of Directors of portfolio companies including FAST, SonarMed, and Grest among others. Doherty also supports other program-related activities.
Doherty has a history of working for entrepreneurial companies. She was vice president of Electronic Evolutions and a co-founder, vice president of Operations and vice president Legal, Human Resources and Administration, and corporate secretary with Escient Technologies. Escient Technologies managed numerous consumer electronic and internet related businesses, including Gracenote® which was purchased by Sony in 2008.
Doherty received her BA and MBA from Indiana University, where she was a member of the honors program. She also received the “Excellence in Leadership” award as special recognition from the professors and administration of Indiana University MBA-CIP for leadership and contribution to the program.